NOV 11, 2015 06:00 AM PST

Clinical next-generation sequencing for precision cancer therapeutics

2 16 869

  • Associate Director, Genetics and Solid Tumor Diagnostics Laboratory, Assistant Professor, Department of Laboratory Medicine, University of Washington
      Dr. Lockwood joined the Department of Laboratory Medicine as an Associate Director of the Genetics and Solid Tumor Diagnostics Laboratory at the University of Washington Medical Center in 2014. She is a Diplomate of the American Board of Clinical Chemistry and an Active Candidate of the American Board of Medical Genetics and Genomics. After obtaining her PhD at the University of Wisconsin, Dr. Lockwood completed postdoctoral fellowship training in Clinical Chemistry and Clinical Molecular Genetics at the Washington University School of Medicine in St. Louis, MO. Her interests include the development and application of molecular methods for the detection of genomic alterations in genetic disease, hematologic malignancies, and solid tumors. Dr. Lockwood has also been active in the design and implementation of educational resources related to training in genomic medicine.


    Next-generation sequencing has emerged as a valuable tool for generating patient-specific genetic information for clinical diagnostics and optimal selection of targeted therapies. The heterogeneous somatic mutational landscape in cancer makes NGS technologies particularly appealing due to their ability to accurately and simultaneously detect multiple mutations across many genes.  Accordingly, oncologists are increasingly recognizing the importance of mutation assessment prior to initiating therapy with targeted therapeutic agents.  Issues that must be considered with NGS include technological limitations and opportunities, bioinformatics, test validation requirements, and reporting complexities. Participants will better understand and assess current clinical NGS testing modalities, including the necessary steps required for selecting a NGS assay.  The presentation will specifically emphasize the utility of NGS testing in precision oncology with illustrative case examples.

    Learning objectives:

    1. Discuss the basic concepts of next-generation sequencing
    2. Define the complexities of detecting somatic mutations using tumor-derived DNA
    3. Describe the advantages and limitations of clinical NGS for precision oncology

    Show Resources
    Loading Comments...